Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 4/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008125 | 0.93 | SMN1; SMN2 (0.49) | SMN1; SMN2ACEMMP8MAPTPIN1 | |
| SCHEMBL8922510 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2ACEMMP8MAPTPIN1 | |
| SCHEMBL7370964 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2MMP8MAPTPIN1L3MBTL1 | |
| SCHEMBL8922709 | 0.82 | ACE (0.45) | SMN1; SMN2ACEMMP8MAPTNPC1 | |
| SCHEMBL3991999 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2ACEMMP8MAPTPIN1 | |
| SCHEMBL1863852 | 0.80 | PPARG (0.45) | SMN1; SMN2ACEPPARGPPARAMEN1 | |
| SCHEMBL18065697 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2MMP8MAPTPIN1PPARG | |
| SCHEMBL935980 | 0.79 | TDP1 (0.59) | SMN1; SMN2MMP8MAPTPIN1L3MBTL1 | |
| SCHEMBL8224624 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2ACEMMP8MAPTPIN1 | |
| SCHEMBL991355 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2MMP8MAPTPIN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | SMN1; SMN2 2869/4885ACE 3665/4885MMP8 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.